MX2016015628A - Profarmacos de gemcitabina. - Google Patents

Profarmacos de gemcitabina.

Info

Publication number
MX2016015628A
MX2016015628A MX2016015628A MX2016015628A MX2016015628A MX 2016015628 A MX2016015628 A MX 2016015628A MX 2016015628 A MX2016015628 A MX 2016015628A MX 2016015628 A MX2016015628 A MX 2016015628A MX 2016015628 A MX2016015628 A MX 2016015628A
Authority
MX
Mexico
Prior art keywords
phosphate
diastereoisomer
relates
gemcitabine
prodrug
Prior art date
Application number
MX2016015628A
Other languages
English (en)
Inventor
Christopher Mcguigan
Griffith Hugh
Serpi Michaela
Ferrari Valentina
Slusarczyk Magdalena
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53499027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016015628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of MX2016015628A publication Critical patent/MX2016015628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Profármaco; esta invención se relaciona con un profármaco del nucleótido monofosfato del medicamento oncológico bien conocido gemcitabina; específicamente, se relaciona con [fenil-benzoxi-L-alaninil)]-fosfato de gemcitabina cuando está presente como un diastereoisómero de fosfato único y, en particular, se relaciona con el diastereoisómero de (S) fosfato el cual proporciona un incremento notorio e inesperado en solubilidad en relación al diastereoisómero (R); el epímero de (S) fosfato también es captado de modo preferencial en soluciones de ciclodextrina con respecto al diastereoisómero (R).
MX2016015628A 2014-06-25 2015-06-25 Profarmacos de gemcitabina. MX2016015628A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
IN2050MU2014 2014-06-25
PCT/GB2015/051857 WO2015198058A1 (en) 2014-06-25 2015-06-25 Gemcitabine prodrugs

Publications (1)

Publication Number Publication Date
MX2016015628A true MX2016015628A (es) 2017-07-04

Family

ID=53499027

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021001140A MX2021001140A (es) 2014-06-25 2015-06-25 Profármacos de gemcitabina.
MX2016015628A MX2016015628A (es) 2014-06-25 2015-06-25 Profarmacos de gemcitabina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021001140A MX2021001140A (es) 2014-06-25 2015-06-25 Profármacos de gemcitabina.

Country Status (28)

Country Link
US (2) US10662213B2 (es)
EP (2) EP3160978B1 (es)
JP (2) JP6982957B2 (es)
KR (2) KR102407935B1 (es)
CN (2) CN106459129B (es)
AU (2) AU2015278899B2 (es)
CA (1) CA2945938C (es)
CL (1) CL2016003260A1 (es)
CY (1) CY1123389T1 (es)
DK (1) DK3160978T3 (es)
EA (1) EA034890B1 (es)
ES (2) ES2811268T3 (es)
HR (2) HRP20230584T1 (es)
HU (2) HUE062474T2 (es)
IL (2) IL248642B (es)
LT (1) LT3160978T (es)
ME (1) ME03817B (es)
MX (2) MX2021001140A (es)
MY (1) MY183198A (es)
NZ (2) NZ725205A (es)
PH (1) PH12016502553A1 (es)
PL (1) PL3160978T3 (es)
PT (1) PT3160978T (es)
RS (1) RS60968B1 (es)
SG (2) SG11201608808TA (es)
SI (1) SI3160978T1 (es)
TW (2) TWI695718B (es)
WO (1) WO2015198058A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY176133A (en) 2012-11-16 2020-07-24 Nucana Biomed Ltd Process for preparing nucleoside prodrugs
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
MX2016015629A (es) 2014-06-25 2017-08-02 Nucana Biomed Ltd Formulacion que comprende un profarmaco de gemcitabina.
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106539810B (zh) * 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
EA037248B1 (ru) 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
EP3386998B1 (en) 2015-12-11 2021-11-10 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN110215469B (zh) * 2019-07-08 2021-11-30 绍兴市人民医院 一种治疗胆管癌的药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
JP4982019B2 (ja) 1999-07-22 2012-07-25 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド 酵素によって触媒される治療活性化
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2595617C (en) 2005-01-27 2014-06-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including ndga compounds, into animals
JP2009504704A (ja) 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
KR20110120886A (ko) 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
AU2010322516A1 (en) 2009-11-20 2012-05-17 Clavis Pharma Asa Parenteral formulations of gemcitabine derivatives
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
MX354990B (es) 2012-01-20 2018-03-28 Aratana Therapeutics Nv Composicion de gotas para los ojos.
MY176133A (en) * 2012-11-16 2020-07-24 Nucana Biomed Ltd Process for preparing nucleoside prodrugs
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
EP3074411A2 (en) * 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucleotides for the treatment of liver cancer
MX2016015629A (es) * 2014-06-25 2017-08-02 Nucana Biomed Ltd Formulacion que comprende un profarmaco de gemcitabina.
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
MX2020009154A (es) 2015-05-14 2022-03-08 NuCana plc Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
EA037248B1 (ru) 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
EP3386998B1 (en) 2015-12-11 2021-11-10 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
SG11201805184TA (en) 2015-12-23 2018-07-30 NuCana plc Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative

Also Published As

Publication number Publication date
EA034890B1 (ru) 2020-04-02
EP3757112B1 (en) 2023-06-07
SG11201608808TA (en) 2016-11-29
IL248642B (en) 2020-03-31
NZ725205A (en) 2023-12-22
TWI695718B (zh) 2020-06-11
HRP20201264T1 (hr) 2021-02-05
TW202033204A (zh) 2020-09-16
PT3160978T (pt) 2020-08-24
TW201613614A (en) 2016-04-16
US10662213B2 (en) 2020-05-26
CN111214480A (zh) 2020-06-02
CA2945938A1 (en) 2015-12-30
CL2016003260A1 (es) 2017-10-06
MX2021001140A (es) 2022-04-21
ES2811268T3 (es) 2021-03-11
KR102407935B1 (ko) 2022-06-10
IL248642A0 (en) 2017-01-31
JP6970236B2 (ja) 2021-11-24
JP6982957B2 (ja) 2021-12-17
EP3757112C0 (en) 2023-06-07
KR20220080220A (ko) 2022-06-14
RS60968B1 (sr) 2020-11-30
KR102563040B1 (ko) 2023-08-02
ES2948660T3 (es) 2023-09-15
EP3757112A1 (en) 2020-12-30
CN106459129A (zh) 2017-02-22
EP3160978B1 (en) 2020-07-29
EP3160978A1 (en) 2017-05-03
TWI758728B (zh) 2022-03-21
HUE053240T2 (hu) 2021-06-28
JP2017519014A (ja) 2017-07-13
SG10201907898SA (en) 2019-09-27
AU2019216626B2 (en) 2020-07-23
PL3160978T3 (pl) 2020-11-30
PH12016502553B1 (en) 2017-04-10
MY183198A (en) 2021-02-18
IL272724B (en) 2021-06-30
AU2019216626A1 (en) 2019-09-05
US20170107246A1 (en) 2017-04-20
AU2015278899B2 (en) 2019-07-18
CA2945938C (en) 2023-04-18
KR20170043479A (ko) 2017-04-21
EA201692312A1 (ru) 2017-04-28
WO2015198058A1 (en) 2015-12-30
NZ765508A (en) 2023-12-22
PH12016502553A1 (en) 2017-04-10
CY1123389T1 (el) 2021-12-31
LT3160978T (lt) 2020-08-25
CN106459129B (zh) 2020-03-31
IL272724A (en) 2020-04-30
US11629164B2 (en) 2023-04-18
HUE062474T2 (hu) 2023-11-28
US20200262861A1 (en) 2020-08-20
DK3160978T3 (da) 2020-08-17
AU2015278899A1 (en) 2016-11-03
JP2020152725A (ja) 2020-09-24
HRP20230584T1 (hr) 2023-09-15
ME03817B (me) 2021-04-20
SI3160978T1 (sl) 2020-11-30

Similar Documents

Publication Publication Date Title
PH12016502553A1 (en) Gemcitabine prodrugs
USD845585S1 (en) Swimsuit
SA517381419B1 (ar) طرق لعلاج حالات الإصابة بعدوى فيروس من عائلة الفيروسات الخيطية
EP3458053A4 (en) USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS
PH12016501633B1 (en) Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
IL263121B (en) History of nucleoside phosphoramidate as anticancer agents
USD886368S1 (en) Cigar airflow adjustment instrument
BR112018012943A2 (pt) forma cristalina de gencitabina
EP3449001A4 (en) INHIBITION OF ARNMI MIR-22 BY APT-110
MX2016010779A (es) Derivados de isoquinoleina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX2016012751A (es) Profarmacos de succionato para uso en el tratamiento de acidosis lactica o efectos secundarios inducidos por farmaco debido al deterioro relacionado con el complejo i de fosforilacion oxidativa mitocondrial.
NZ720106A (en) A process for the preparation of regadenoson
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
EP3518954A4 (en) METHOD FOR PRODUCING ANTITUARY AGENT AGAINST TUMOR VASCULATURE
EP3662075A4 (en) IMPROVED PRODUCTION OF RHAMNOLIPIDS USING AT LEAST TWO SOURCES OF CARBON
MY180413A (en) Process for the decomposition of lignocellulose-containing biomass-material
IN2013MU01219A (es)
EA202090269A3 (ru) Продукты гемцитабина
IL274808B1 (en) Phosphoramidate diphosphate salts of nucleosides as anticancer compounds
MX370971B (es) Proceso de produccion de ciclo-deshidrolinalool (ii).
BR112017018992A2 (pt) processo de preparação de derivados de fenilisoxazolina substituída
MY187230A (en) A composition for inhibiting proliferation of cancer cells